Good morning, everyone! As we start a new work week, let’s get back into the routine with a cup of pistachio creme and some interesting news. GSK is leaving the biotechnology industry trade group BIO, following other companies like Pfizer and UCB. The pharmaceutical industry may have a chance to adjust the Medicare drug pricing negotiation law with Republicans in power. Additionally, a report from Regulatory Focus shows that India, China, and Europe are major players in manufacturing active pharmaceutical ingredients for the U.S. market. India leads globally in active DMFs, followed by the EU, China, and the U.S. Keep up the good work and have a productive day!
Source link
GSK leaving BIO; an AbbVie schizophrenia drug failed in two trials
